

## Contents

**Preface** *XIII*

**List of Contributors** *XVII*

### **Part I HDAC Inhibitor Anticancer Drug Discovery** *1*

- 1 From DMSO to the Anticancer Compound SAHA, an Unusual Intellectual Pathway for Drug Design** *3*  
*Ronald Breslow*
  - 1.1 Introduction *3*
  - 1.2 The Discovery of SAHA (vorinostat) *4*
  - 1.3 Clinical Trials *7*
  - 1.4 Follow-On Research – Selective HDAC Inhibitors *8*
  - 1.5 Conclusion *9*
  - References *9*
  
- 2 Romidepsin and the Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors** *13*  
*A. Ganesan*
  - 2.1 Histone Deacetylases as a Therapeutic Target *13*
  - 2.2 The Discovery and Development of Romidepsin *15*
  - 2.3 The Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors *18*
  - 2.4 Synthetic Analogues of the Zinc-Binding Thiol Natural Products *21*
  - 2.5 Summary *23*
  - References *24*
  
- 3 The Discovery and Development of Belinostat** *31*  
*Paul W. Finn, Einars Loza and Elisabeth Carstensen*
  - 3.1 Introduction *31*
  - 3.2 Discovery of Belinostat *32*
    - 3.2.1 Design Strategy *32*
    - 3.2.2 Medicinal Chemistry and SAR *34*

3.3	Belinostat Biological Profiling	41
3.3.1	Mode of Action and HDAC Isoform Selectivity	41
3.3.2	Antiproliferative and Antitumor Activity	42
3.4	Formulation Development	44
3.5	Clinical Development	45
3.5.1	Clinical Studies Leading to Approval and Other Clinical Investigations	45
3.5.2	Pharmacokinetics	49
3.5.3	Safety and Tolerability	51
3.6	Conclusions	52
	References	53
<b>4</b>	<b>Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug</b>	<b>59</b>
	<i>Peter Atadja and Lawrence Perez</i>	
4.1	Target Identification: From p21 <sup>Waf1</sup> Induction to HDAC Inhibition	59
4.2	Program Flowchart Assays for Drug Discovery	61
4.3	Hit-To-Lead Campaign: Trichostatin A to LAK974	63
4.4	Lead Optimization: LAK974 to LAQ824	64
4.5	Profiling LAQ824 for Cancer Therapy	66
4.6	Preclinical Development of LAQ824	70
4.7	LAQ824 Follow-Up	72
4.8	Discovery of LBH589	73
4.9	Safety Profile for LBH589	74
4.10	Pan-HDAC Inhibition by LBH589	76
4.11	Cancer Cell-Specific Cytotoxicity of LBH589	76
4.11.1	Toxicity and Safety Studies with LBH589	78
4.11.2	Early Clinical Activity of LBH589 in CTCL	78
4.11.3	Large-Scale Cell Line Profiling to Discover Lineage-Specific LBH589-Sensitive Cancer Indications	79
4.11.4	Clinical Profiling of Heme Malignancies for LBH589 Activity	80
4.11.5	Phase II Study of Oral Panobinostat in Hodgkin Lymphoma	81
4.11.6	Phase IB Clinical Studies in Multiple Myeloma	82
4.11.7	Phase III Registration Study in Relapsed or Refractory Myeloma	82
4.11.8	Conclusion and Future Perspective	83
	References	85
<b>5</b>	<b>Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers</b>	<b>89</b>
	<i>Xian-Ping Lu, Zhi-Qiang Ning, Zhi-Bin Li, De-Si Pan, Song Shan, Xia Guo, Hai-Xiang Cao, Jin-Di Yu and Qian-Jiao Yang</i>	
5.1	Introduction	89
5.1.1	Epigenetics and Cancer	89
5.1.2	Epigenetic Drugs	90
5.2	Discovery of Chidamide	93

5.2.1	Identification of Chemical Scaffold	93
5.2.2	Design and Screening New Selective Benzamide HDAC Inhibitors	93
5.2.3	Molecular Docking of Chidamide with HDAC2	95
5.3	Molecular Mechanisms of Chidamide	97
5.3.1	Selectivity	97
5.3.2	Induction of Cell Cycle Arrest, Apoptosis and Differentiation of Tumour Cells	98
5.3.3	Reversal of Epithelial to Mesenchymal Transition	99
5.3.4	Stimulation of Innate and Antigen-Specific Antitumour Immunity	99
5.3.5	Multiplicity of Anticancer Mechanisms by Chidamide	100
5.4	Animal Studies	101
5.5	Clinical Development	101
5.5.1	Pharmacokinetics and Pharmacodynamics	101
5.5.2	Unmet Medical Needs for Peripheral T-Cell Lymphoma (PTCL)	102
5.5.3	Efficacy Assessment of Chidamide in PTCL Patients	103
5.5.4	Safety Profile	105
5.6	Future Perspective	106
	References	108

## Part II Steroidal CYP17 Inhibitor Anticancer Drug Discovery 115

6	<b>Abiraterone Acetate (Zytiga): An Inhibitor of CYP17 as a Therapeutic for Castration-Resistant Prostate Cancer</b>	117
	<i>Gabriel M. Belfort, Boyd L. Harrison and Gabriel Martinez Botella</i>	
6.1	Introduction	117
6.2	Discovery and Structure–Activity Relationships (SAR)	119
6.3	Preclinical Characterisation of Abiraterone and Abiraterone Acetate	126
6.3.1	Pharmacology	126
6.3.2	Pharmacokinetics	127
6.3.3	Toxicology	128
6.4	Physical Characterisation	129
6.5	Clinical Studies	129
6.6	Conclusion	132
	References	133

## Part III Anti-Infective Drug Discoveries 137

7	<b>Discovery of Delamanid for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis</b>	139
	<i>Hidetsugu Tsubouchi, Hirofumi Sasaki, Hiroshi Ishikawa and Makoto Matsumoto</i>	
7.1	Introduction	139

7.2	Synthesis Strategy	140
7.3	Synthesis Route	142
7.4	Screening Evaluations	145
7.4.1	Screening Procedure	145
7.4.2	Screening Results	146
7.4.3	Selection of a Compound Candidate for Preclinical Tests	151
7.5	Preclinical Data of Delamanid	151
7.5.1	Antituberculosis Activity	151
7.5.2	Mechanism of Action	153
7.5.3	Pharmacokinetics	153
7.5.4	Genotoxicity and Carcinogenicity	154
7.5.5	Preclinical Therapeutic Efficacy	154
7.6	Clinical Data of Delamanid	155
7.6.1	Clinical Pharmacokinetics	155
7.6.2	Drug–Drug Interactions	156
7.6.3	Cardiovascular Safety	156
7.6.4	Clinical Therapeutic Efficacy	156
7.6.5	Other Clinical Trials	157
7.7	Future Priorities and Conclusion	158
	References	159
<b>8</b>	<b>Sofosbuvir: The Discovery of a Curative Therapy for the Treatment of Hepatitis C Virus</b>	<b>163</b>
	<i>Michael J. Sofia</i>	
8.1	Introduction	163
8.2	Discussion	165
8.2.1	Target Rationale: HCV NS5B RNA-Dependent RNA Polymerase	165
8.2.2	Rationale and Design of a Liver Targeted Nucleotide Prodrug	168
8.2.3	Prodrug Optimization and Preclinical Evaluation	171
8.2.4	Prodrug Metabolism	175
8.2.5	Clinical Proof of Concept of a Liver Targeted Nucleotide Prodrug	176
8.2.6	The Single Diastereomer: Sofosbuvir	176
8.2.7	Sofosbuvir Preclinical Profile	177
8.2.8	Sofosbuvir Clinical Studies	179
8.2.9	Viral Resistance	182
8.3	Conclusion	183
	References	184

**Part IV Central Nervous System (CNS) Drug Discovery 189**

- 9 The Discovery of the Antidepressant Vortioxetine and the Research that Uncovered Its Potential to Treat the Cognitive Dysfunction Associated with Depression 191**  
*Benny Bang-Andersen, Christina Kurre Olsen and Connie Sánchez*
- 9.1 Introduction 191
- 9.2 The Discovery of Vortioxetine 192
- 9.3 Clinical Development of Vortioxetine for the Treatment of MDD 200
- 9.4 Uncovering Vortioxetine's Potential to Treat Cognitive Dysfunction in Patients with MDD 201
- 9.4.1 Early Preclinical Evidence that Differentiated Vortioxetine from Other Antidepressants 201
- 9.4.2 Vortioxetine's Primary Targets and Their Putative Impact on Cognitive Function – Early Preclinical Data 202
- 9.4.3 Hypothesis-Generating Clinical Study of Vortioxetine's Effects on Cognitive Symptoms in Elderly Patients with MDD 203
- 9.4.4 Substantiation of a Mechanistic Rationale for the Procognitive Effects of Vortioxetine in Preclinical Models and Its Differentiation from SSRIs and SNRIs 204
- 9.4.5 Confirmation of the Cognitive Benefits of Vortioxetine in Two Large Placebo-Controlled Studies in Adults with MDD 205
- 9.4.6 Additional Translational Evidence of the Effect of Vortioxetine on Brain Activity During Cognitive Performance 208
- 9.5 Conclusion 208
- References 210

**Part V Antiulcer Drug Discovery 215**

- 10 Discovery of Vonoprazan Fumarate (TAK-438) as a Novel, Potent and Long-Lasting Potassium-Competitive Acid Blocker 217**  
*Haruyuki Nishida*
- 10.1 Introduction 217
- 10.2 Limitations of PPIs and the Possibility of P-CABs 218
- 10.3 Exploration of Seed Compounds 220
- 10.4 Lead Generation from HTS Hit Compound 1 220
- 10.5 Analysis of SAR and Structure–Toxicity Relationship for Lead Optimization 223
- 10.6 Selection of Vonoprazan Fumarate (TAK-438) as a Candidate Compound 224
- 10.7 Preclinical Study of TAK-438 226
- 10.8 Clinical Study of TAK-438 228
- 10.9 Discussion 229
- 10.10 Conclusion 230
- References 232

**Part VI Cross-Therapeutic Drug Discovery  
(Respiratory Diseases/Anticancer) 235**

<b>11</b>	<b>Discovery and Development of Nintedanib: A Novel Antiangiogenic and Antifibrotic Agent 237</b>
	<i>Gerald J. Roth, Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Rozsa Schlenker-Herceg, Frank Hilberg, Lutz Wollin, John Park, Alexander Pautsch and Rolf Kaiser</i>
11.1	Introduction 237
11.2	Structure–Activity Relationships of Oxindole Kinase Inhibitors and the Discovery of Nintedanib 238
11.3	Structural Research 244
11.4	Preclinical Pharmacodynamic Exploration 246
11.4.1	Kinase Inhibition Profile of Nintedanib 246
11.4.2	Oncology, Disease Pathogenesis and Mechanism of Action 246
11.4.3	Idiopathic Pulmonary Fibrosis, Disease Pathogenesis and Mechanism of Action 249
11.5	Nonclinical Drug Metabolism and Pharmacokinetics 250
11.6	Clinical Pharmacokinetics 251
11.7	Toxicology 252
11.8	Phase III Clinical Data 253
11.8.1	Efficacy and Safety of Nintedanib in IPF 253
11.8.2	Efficacy and Safety of Nintedanib in NSCLC 255
11.9	Other Oncology Studies 256
11.10	Conclusions 257
	References 258
	<b>Index 267</b>